Preface |
|
xi | |
Introduction |
|
xiii | |
About the Author |
|
xvii | |
|
Chapter 1 Laboratory Tests |
|
|
1 | (178) |
|
Alanine transaminase (ALT) |
|
|
2 | (3) |
|
|
5 | (2) |
|
Alkaline phosphatase (ALP) |
|
|
7 | (3) |
|
|
10 | (1) |
|
|
11 | (2) |
|
|
13 | (2) |
|
Antinuclear antibody (ANA) test |
|
|
15 | (3) |
|
Apolipoprotein E (ApoE) genotyping |
|
|
18 | (1) |
|
Aspartate transaminase (AST) |
|
|
19 | (3) |
|
Basic metabolic panel (BMP) |
|
|
22 | (1) |
|
|
23 | (3) |
|
Blood alcohol level (BAL) |
|
|
26 | (2) |
|
Blood urea nitrogen (BUN) |
|
|
28 | (2) |
|
|
30 | (4) |
|
|
34 | (1) |
|
Carbohydrate-deficient transferrin (CDT or %CDT) |
|
|
35 | (2) |
|
|
37 | (2) |
|
|
39 | (2) |
|
|
41 | (1) |
|
|
42 | (2) |
|
|
44 | (1) |
|
|
45 | (1) |
|
Complete blood count (CBC) |
|
|
46 | (2) |
|
Comprehensive metabolic panel (CMP) |
|
|
48 | (1) |
|
Cranial computed tomography (head CT or CAT scan) |
|
|
49 | (3) |
|
Creatine kinase (CK) (also known as creatine phosphokinase [ CPK]) |
|
|
52 | (4) |
|
|
56 | (3) |
|
Cytochrome P450 (CYP450) genotyping: AmpliChip CYP450 test |
|
|
59 | (2) |
|
|
61 | (1) |
|
Drug screen (toxicology screen) |
|
|
62 | (3) |
|
Electrocardiogram (ECG or EKG) |
|
|
65 | (3) |
|
Electroencephalogram (EEG) |
|
|
68 | (3) |
|
|
71 | (1) |
|
|
72 | (1) |
|
|
73 | (1) |
|
Folate (also known as folic acid) |
|
|
74 | (2) |
|
Gamma-glutamyltransferase (GGT) |
|
|
76 | (2) |
|
|
78 | (3) |
|
|
81 | (2) |
|
|
83 | (2) |
|
|
85 | (2) |
|
|
87 | (2) |
|
|
89 | (2) |
|
|
91 | (2) |
|
|
93 | (4) |
|
|
97 | (2) |
|
Liver function tests (LFTs) |
|
|
99 | (3) |
|
|
102 | (1) |
|
|
103 | (3) |
|
Magnetic resonance imaging (MRI) |
|
|
106 | (4) |
|
Mean corpuscular volume (MCV) |
|
|
110 | (2) |
|
|
112 | (1) |
|
Multiple sleep latency test (MSLT); maintenance of wakefulness test (MWT) |
|
|
113 | (2) |
|
Osmolality (serum and urine) |
|
|
115 | (4) |
|
|
119 | (1) |
|
Phosphate (also known as phosphorus) |
|
|
120 | (3) |
|
|
123 | (3) |
|
|
126 | (2) |
|
Positron emission tomography (PET): brain |
|
|
128 | (2) |
|
|
130 | (3) |
|
|
133 | (2) |
|
|
135 | (3) |
|
|
138 | (2) |
|
|
140 | (2) |
|
Red blood cell count (RBC) |
|
|
142 | (2) |
|
|
144 | (1) |
|
Single-photon emission computed tomography (SPECT) |
|
|
145 | (2) |
|
|
147 | (2) |
|
|
149 | (2) |
|
|
151 | (1) |
|
|
152 | (2) |
|
Thyroid function testing: free thyroxine (free T4; FT4) |
|
|
154 | (2) |
|
Thyroid function testing: thyroid-stimulating hormone (TSH) |
|
|
156 | (3) |
|
|
159 | (3) |
|
Tuberculosis (TB) testing |
|
|
162 | (2) |
|
|
164 | (2) |
|
|
166 | (3) |
|
|
169 | (1) |
|
|
170 | (2) |
|
|
172 | (2) |
|
White blood cell count (WBC) |
|
|
174 | (2) |
|
Wilson disease screening panel |
|
|
176 | (3) |
|
Chapter 2 Diseases and Conditions |
|
|
179 | (60) |
|
Alcohol use disorder (alcoholism) |
|
|
180 | (2) |
|
|
182 | (2) |
|
Anxiety disorder (secondary): substance/medication-induced or due to another medical condition |
|
|
184 | (1) |
|
Attention-deficit/hyperactivity disorder (ADHD) |
|
|
185 | (1) |
|
Autism spectrum disorder (ASD) |
|
|
186 | (1) |
|
Catatonia disorder due to another medical condition |
|
|
187 | (1) |
|
|
188 | (2) |
|
|
190 | (1) |
|
Down syndrome (trisomy 21) |
|
|
191 | (1) |
|
|
192 | (2) |
|
Ethylene glycol poisoning |
|
|
194 | (1) |
|
Fatty liver disease (nonalcoholic) |
|
|
195 | (1) |
|
|
196 | (1) |
|
Generalized anxiety disorder (GAD) |
|
|
197 | (1) |
|
Hepatic encephalopathy (HE) |
|
|
198 | (2) |
|
|
200 | (1) |
|
|
201 | (2) |
|
|
203 | (1) |
|
|
204 | (2) |
|
|
206 | (1) |
|
|
207 | (1) |
|
|
208 | (2) |
|
|
210 | (1) |
|
|
211 | (2) |
|
|
213 | (1) |
|
|
214 | (1) |
|
Neuroleptic malignant syndrome (NMS) |
|
|
215 | (1) |
|
Obsessive-compulsive disorder (OCD) |
|
|
216 | (1) |
|
Panic attack; panic disorder |
|
|
217 | (2) |
|
|
219 | (1) |
|
|
220 | (1) |
|
Psychotic disorder due to another medical condition |
|
|
221 | (2) |
|
Restless legs syndrome (RLS) |
|
|
223 | (1) |
|
|
224 | (2) |
|
|
226 | (2) |
|
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) |
|
|
228 | (2) |
|
Thiamine (vitamin B1) deficiency |
|
|
230 | (2) |
|
|
232 | (2) |
|
|
234 | (2) |
|
Wernicke-Korsakoff syndrome |
|
|
236 | (3) |
|
Chapter 3 Psychotropic Medications: Laboratory Screening and Monitoring |
|
|
239 | (38) |
|
|
240 | (1) |
|
Amphetamines (Adderall); dextroamphetamines (Dexedrine); lisdexamfetamine dimesylate (Vyvanse) |
|
|
241 | (1) |
|
Antipsychotic medications, first-generation (typical) |
|
|
242 | (1) |
|
Antipsychotic medications, second-generation (atypical) |
|
|
243 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
Buprenorphine (Buprenex, Subutex); buprenorphine/naloxone (Suboxone) |
|
|
246 | (1) |
|
Bupropion (Aplenzin, Budeprion SR, Wellbutrin) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
249 | (1) |
|
Clozapine (Clozaril, FazaClo, Versacloz) |
|
|
250 | (2) |
|
|
252 | (1) |
|
|
253 | (1) |
|
|
254 | (1) |
|
|
255 | (1) |
|
|
256 | (1) |
|
|
257 | (1) |
|
|
258 | (1) |
|
Methylphenidate (Ritalin, Concern) |
|
|
259 | (1) |
|
|
260 | (1) |
|
Monoamine oxidase inhibitors (MAOIs) |
|
|
261 | (1) |
|
Naltrexone (ReVia, Vivitrol) |
|
|
262 | (1) |
|
|
263 | (1) |
|
Nonbenzodiazepine hypnotics: eszopiclone (Lunesta), zaleplon (Sonata), Zolpidem (Ambien, Edluar, Intermezzo, Zolpimist) |
|
|
264 | (1) |
|
|
265 | (1) |
|
Oxcarbazepine (Trileptal) |
|
|
266 | (1) |
|
|
267 | (1) |
|
|
268 | (1) |
|
Selective serotonin reuptake inhibitors (SSRIs) |
|
|
269 | (1) |
|
|
270 | (1) |
|
|
271 | (1) |
|
Trazodone (Desyrel, Oleptro) |
|
|
272 | (1) |
|
Tricyclic antidepressants (TCAs) |
|
|
273 | (2) |
|
|
275 | (1) |
|
Venlafaxine (Effexor); desvenlafaxine (Pristiq) |
|
|
276 | (1) |
|
|
277 | (10) |
|
Therapeutic and Toxic Drug Levels at a Glance |
|
|
279 | (1) |
|
Ten Rules for a Normal Electrocardiogram |
|
|
280 | (7) |
|
Figure 1 The Electrocardiogram: Waves and Intervals |
|
|
281 | (1) |
|
|
282 | (1) |
|
Figure 3 Cholestatic Injury |
|
|
282 | (1) |
|
|
283 | (1) |
|
Figure 5 Syndrome of inappropriate antidiuretic hormone secretion (SIADH) |
|
|
284 | (3) |
References |
|
287 | (8) |
Index |
|
295 | |